# “Strike Early and Strike Strong”: Low LDL-Cholesterol and Low Albumin Predict Statin Hyporesponsiveness in Acute Coronary Syndrome

## TL;DR

This study finds that patients with low LDL-cholesterol and low albumin levels are more likely to not respond well to high-dose statin therapy after a heart attack.

## Contribution

The study identifies a novel predictive model using baseline LDL-C and albumin levels to identify statin hyporesponsive patients early.

## Key findings

- 63.1% of patients with ACS were hyporesponsive to high-intensity statin therapy.
- Low baseline LDL-C and albumin levels strongly predicted hyporesponsiveness.
- A combined model of LDL-C and albumin showed better predictive performance (AUC: 0.670).

## Abstract

Background/Objectives: Many patients with acute coronary syndrome (ACS) fail to achieve adequate low-density lipoprotein-cholesterol (LDL-C) reduction, despite receiving high-intensity statin therapy. Identifying patients requiring early combination therapy remains a challenging task. This study aimed to determine the prevalence of statin hyporesponsiveness in patients with ACS and investigate the predictive role of baseline LDL-C and albumin levels. Methods: This retrospective study enrolled 366 patients with ACS treated with high-intensity statins (atorvastatin 40–80 mg). Hyporesponsiveness was defined as LDL-C reduction of <50% at 21–28 d. The baseline parameters were analyzed using logistic regression and receiver operating characteristic (ROC) curve analysis. Results: Hyporesponsiveness was observed in 63.1% of patients. Hyporesponders had significantly lower baseline albumin (41.7 vs. 43.3 g/L, p = 0.0002) and LDL-C (126.6 vs. 147.3 mg/dL, p < 0.0001) levels. Categorical analysis revealed that the combination of baseline LDL-C < 100 mg/dL and albumin < 40 g/L predicted hyporesponsiveness in 95.7% of cases. ROC curve analysis identified optimal predictive cut-offs of 128.50 mg/dL for LDL-C (area under the curve (AUC): 0.652) and 41.15 g/L for albumin (AUC: 0.618). The combined LDL-C + albumin model demonstrated superior predictive performance with an AUC of 0.670 (95% CI: 0.615–0.725). Conclusions: Low baseline LDL-C and low albumin are strong predictors of statin hyporesponsiveness in patients with ACS. These routinely obtained biomarkers can identify very high-risk patients who may benefit from proactive combination lipid-lowering therapy from hospital discharge, supporting the “strike early and strike strong” strategy and challenging the traditional stepwise approach.